SCHEMBL205451

SCHEMBL205451

C1=NSc2ccccc2N1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 6/20 0.39
MAPT P10636 6/20 0.39
NOX1 Q9Y5S8 4/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
TDP1 Q9NUW8 2/20 0.39
CYP1A2 P05177 1/20 0.39
BCHE P06276 1/20 0.39
POLB P06746 1/20 0.39
CYP3A4 P08684 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
ALOX15 P16050 1/20 0.39
ALOX12 P18054 1/20 0.39
MAOA P21397 1/20 0.39
CNR1 P21554 1/20 0.39
ACHE P22303 1/20 0.39
PTGS1 P23219 1/20 0.39
SLC6A2 P23975 1/20 0.39
HTR2C P28335 1/20 0.39
PTGS2 P35354 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27845556 0.71 NOX1 (0.34) MAPTNOX1CYP1A2BCHECYP3A4
SCHEMBL2802574 0.67
SCHEMBL5824133 0.64 NOX1 (0.50) GAAMAPTNOX1MEN1KMT2A
SCHEMBL57942 0.64
SCHEMBL8490363 0.62
SCHEMBL3527559 0.62 GAA (0.44) GAAMAPTNOX1MEN1KMT2A
SCHEMBL5803498 0.62
SCHEMBL207246 0.62 GAA (0.38) GAAMAPTNOX1MEN1KMT2A
SCHEMBL11852004 0.61 NOX1 (0.46) GAAMAPTNOX1MEN1KMT2A
SCHEMBL22016048 0.61 MAPT (0.46) GAAMAPTNOX1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 754 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4566670-A2 MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS Gilead Sciences, Inc. (US) 2025-06-11 EP claimed
EP-4403221-A2 MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS Gilead Sciences, Inc. (US) 2024-07-24 EP claimed
CN-110204510-B Method for synthesizing 1,2, 4-benzothiadiazine series compound in aqueous solution 江西师范大学 2022-05-24 CN claimed
EP-3696171-A1 MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS Gilead Sciences, Inc. (US) 2020-08-19 EP claimed
EP-3112355-A1 MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS GILEAD SCIENCES, INC. (US) 2017-01-04 EP claimed
US-20160303088-A1 MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS GILEAD SCIENCES, INC. 2016-10-20 US claimed
EP-2487165-B1 Modulators of pharmacokinetic properties of therapeutics GILEAD SCIENCES INC (US) 2016-09-14 EP claimed
EP-2487161-B1 Modulators of pharmacokinetic properties of therapeutics GILEAD SCIENCES INC (US) 2016-08-10 EP claimed
EP-2231628-B1 INHIBITORS OF CYTOCHROME P450 GILEAD SCIENCES INC (US) 2015-10-28 EP claimed
US-9139541-B2 Modulators of pharmacokinetic properties of therapeutics GILEAD SCIENCES, INC. (US) 2015-09-22 US claimed
US-20080008682-A1 Modulators of toll-like receptor 7 GILEAD SCIENCES, INC. 2008-01-10 US claimed
WO-2008005555-A1 MODULATORS OF TOLL-LIKE RECEPTOR 7 GILEAD SCIENCES, INC. (US) 2008-01-10 WO claimed
WO-2008005542-A2 ANTIVIRAL PHOSPHINATE COMPOUNDS GILEAD SCIENCES, INC., (US) 2008-01-10 WO claimed
US-20070173440-A1 Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection SCYNEXIS, INC. 2007-07-26 US claimed
US-7235548-B2 Compounds and their use as positive AMPA receptor modulators NEUROSEARCH A/S (DK) 2007-06-26 US claimed
WO-2007041632-A2 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF HEPATITIS C INFECTION SCYNEXIS, INC. (US) 2007-04-12 WO claimed
WO-2006091798-A2 VACCINES AND METHODS FOR PREVENTION AND TREATMENT OF DRUG-RESISTANT HIV-1 AND HEPATITIS B VIRUS THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2006-08-31 WO claimed
EP-0977738-B1 CYCLIN DEPENDENT KINASE (CDK)4 INHIBITORS AND THEIR USE FOR TREATING CANCER US HEALTH (US) 2005-11-16 EP claimed
US-20040043987-A1 Novel compounds and their use as positive AMPA receptor modulators NEUROSEARCH A/S. 2004-03-04 US claimed
US-4178374-A SUBSTITUTED 1,2,5-THIADIAZOLE B-ADRENERGIC BLOCKING AGENT, PYRAZINE AND/OR THIAZIDE DIURETIC, TREATMENT OF HYPERTENSION MERCK & CO., INC. (US) 1979-12-11 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160303088-A1 MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS SLC10A1, SLC10A2, ABCB11 GAA 295/4885MAPT 1806/4885NOX1 4046/4885
US-20070173440-A1 Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection HAVCR2, C1R, C1S GAA 1200/4885MAPT 4165/4885NOX1 2572/4885
US-20040043987-A1 Novel compounds and their use as positive AMPA receptor modulators GRIK4, GRIA4, GRM2 GAA 4482/4885MAPT 4215/4885NOX1 3161/4885
US-20080008682-A1 Modulators of toll-like receptor 7 TLR7, TLR6, TLR3 GAA 1631/4885MAPT 4446/4885NOX1 2257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.